Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Jackson

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
British Journal of Haematology|April 27, 2012
Organ-specific management and supportive care in chronic graft-versus-host diseaseFiona L Dignan, Julia J Scarisbrick, Jacqueline Cornish, et al.
Blood|December 15, 2011
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Myriam Labopin, Arnon Nagler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasiaSudhir Tauro, Charles Craddock, Karl Peggs, et al.
Blood|August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosisDavid C Johnson, Oleg Lenive, Jonathan Mitchell, et al.
Haematologica|June 7, 2021
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patientsNiels Weinhold, Hans J Salwender, David A Cairns, et al.
International Journal of Clinical Practice|October 25, 2016
Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME)Mario Maggi, Frederick C W Wu, Thomas H Jones, et al.
Leukemia|March 12, 2020
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patientsVallari Shah, Amy L Sherborne, David C Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.
Blood|September 23, 2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotypingDavid C Johnson, Sophie Corthals, Christine Ramos, et al.
The Journal of Urology|January 15, 2013
Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular riskAjay Nehra, Graham Jackson, Martin Miner, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
British Journal of Haematology|April 27, 2012
Organ-specific management and supportive care in chronic graft-versus-host diseaseFiona L Dignan, Julia J Scarisbrick, Jacqueline Cornish, et al.
Blood|December 15, 2011
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Myriam Labopin, Arnon Nagler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasiaSudhir Tauro, Charles Craddock, Karl Peggs, et al.
Blood|August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosisDavid C Johnson, Oleg Lenive, Jonathan Mitchell, et al.
Haematologica|June 7, 2021
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patientsNiels Weinhold, Hans J Salwender, David A Cairns, et al.
International Journal of Clinical Practice|October 25, 2016
Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME)Mario Maggi, Frederick C W Wu, Thomas H Jones, et al.
Leukemia|March 12, 2020
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patientsVallari Shah, Amy L Sherborne, David C Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.
Blood|September 23, 2008
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotypingDavid C Johnson, Sophie Corthals, Christine Ramos, et al.
The Journal of Urology|January 15, 2013
Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular riskAjay Nehra, Graham Jackson, Martin Miner, et al.
Pageof 26